Pharmacological chaperone
Pharmacological chaperones are a type of drug that bind to proteins to assist in their folding, stability, and transport. They are a promising approach for the treatment of diseases caused by protein misfolding, such as cystic fibrosis, Alzheimer's disease, and Parkinson's disease.
Mechanism of Action[edit]
Pharmacological chaperones work by binding to unstable or misfolded proteins, stabilizing them and helping them to fold correctly. This can increase the functional activity of the protein and reduce the harmful effects of protein misfolding.
Applications[edit]
Pharmacological chaperones have potential applications in a wide range of diseases caused by protein misfolding. These include:
- Cystic fibrosis: Pharmacological chaperones can help correct the misfolding of the CFTR protein, which causes cystic fibrosis.
- Alzheimer's disease: Pharmacological chaperones can stabilize the tau protein, reducing the formation of neurofibrillary tangles that contribute to Alzheimer's disease.
- Parkinson's disease: Pharmacological chaperones can stabilize the alpha-synuclein protein, reducing the formation of Lewy bodies that contribute to Parkinson's disease.
Research and Development[edit]
Research into pharmacological chaperones is ongoing, with several drugs currently in clinical trials. These include:
- Lumacaftor: A pharmacological chaperone for the treatment of cystic fibrosis.
- Tafamidis: A pharmacological chaperone for the treatment of transthyretin amyloidosis.
See Also[edit]
References[edit]